
Opinion|Videos|June 28, 2024
Analyzing the MARIPOSA-2 Trial Data’s Impact on Clinical Practice
Cara Chang, PharmD, BCOP, provides a comprehensive analysis of the MARIPOSA-2 trial, evaluating the various study arms and interpreting the practice-changing data presented.
Advertisement
Episodes in this series

- The
MARIPOSA-2 trial, a recent publication from January, assessed patients with Ex19del or Ex21 L858R mutations who had progressed on osimertinib. It compared three treatment arms: amivantamab plus lazertinib plus chemotherapy, amivantamab plus chemotherapy (without lazertinib), and chemotherapy alone. What are the significant findings of this study, and what are the key insights that could influence clinical practice? - When it comes to patients with S768I, L861Q, and/or G719X mutations, how does their treatment approach differ from (or is similar to) those observed in the FLAURA2 and MARIPOSA / MARIPOSA-2 studies?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Men Face Higher Odds of Later-Stage Diagnosis Across 20 Cancer Types
2
Investigational mRNA Flu Vaccine Broadens Antibody Defenses, Sustains Immune "Training Hub" Longer Than Standard Shot
3
FDA Approves Enlicitide, the First Oral PCSK9 Inhibitor for High Cholesterol
4
FDA Accepts NDA for AD109 to Treat of Adults With Obstructive Sleep Apnea
5






































































































